---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-072931"
form_type: "8-K"
ticker: "XAGE"
cik: "0001842939"
company_name: "Longevity Health Holdings, Inc."
filed_at: "2025-05-16T23:59:59+00:00"
generated_at: "2026-05-21T03:35:53.413097+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Longevity Health Q1 pro forma sales $663k, merger with 20/20 BioLabs progressing

## Summary
- XAGE Q1 unaudited pro forma sales ~$663k (+8% YoY); 20/20 sales ~$562k (+15% YoY).
- Merger agreement with 20/20 signed April 11; S-4 filed May 8; closing subject to conditions.
- 1-for-30 reverse stock split completed May 12; trading at split-adjusted price from May 14.
- Expected Q2 launches: XAGE medicated cleanser, 20/20 inflammatory biomarker test, and OneTest pilot with Giant Food.
- Company evaluating options for additional financing, anticipates primary investment in Q2 2025.

## SEC filing metadata
- accession: 0000950170-25-072931
- form_type: 8-K
- ticker: XAGE
- cik: 0001842939
- company_name: Longevity Health Holdings, Inc.
- filed_at: 2025-05-16T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1842939/000095017025072931/0000950170-25-072931-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1842939/000095017025072931/xage-20250515.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-072931
- JSON: https://secwatch.observer/filing/0000950170-25-072931.json
- Plain text: https://secwatch.observer/filing/0000950170-25-072931.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.